Search research articles
Contact Us
Filters
Showing results (61-70 of 126) with videos related to
Page
of 13
Sort By:
European Journal of Haematology
|
January 14, 2022
Identifying patients with chronic lymphocytic leukemia without need of treatment: End of endless watch and wait?
Christian Brieghel, Veerle Galle, Rudi Agius, et al.
British Journal of Cancer
|
May 16, 2019
The anaphase-promoting complex/cyclosome: a new promising target in diffuse large B-cell lymphoma and mantle cell lymphoma
Anke Maes, Ken Maes, Hendrik De Raeve, et al.
British Journal of Haematology
|
November 14, 2013
Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma
Michelle Fanale, Sarit Assouline, John Kuruvilla, et al.
American Journal of Hematology
|
May 26, 2016
A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL
Ian W Flinn, Panayiotis Panayiotidis, Boris Afanasyev, et al.
Clinical Hematology International
|
January 19, 2023
Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma
Torben Plesner, Simon J Harrison, Hang Quach, et al.
Blood
|
July 30, 2025
Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL
Jan A Burger, Paul M Barr, Tadeusz Robak, et al.
British Journal of Haematology
|
November 27, 2013
Peripheral blood involvement in patients with follicular lymphoma: a rare disease manifestation associated with poor prognosis
Clémentine Sarkozy, Lucile Baseggio, Pierre Feugier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 26, 2015
A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma
Markus Hansson, Peter Gimsing, Ashraf Badros, et al.
Blood
|
August 14, 2012
Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms
Hervé Ghesquières, Guillaume Cartron, John Francis Seymour, et al.
Targeted Oncology
|
October 23, 2021
Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study
Eliza A Hawkes, Tycel Phillips, Lihua Elizabeth Budde, et al.
Page
of 13
Search research articles
Search
Showing results (61-70 of 126) with videos related to
Sort By:
Page
of 13
European Journal of Haematology
|
January 14, 2022
Identifying patients with chronic lymphocytic leukemia without need of treatment: End of endless watch and wait?
Christian Brieghel, Veerle Galle, Rudi Agius, et al.
British Journal of Cancer
|
May 16, 2019
The anaphase-promoting complex/cyclosome: a new promising target in diffuse large B-cell lymphoma and mantle cell lymphoma
Anke Maes, Ken Maes, Hendrik De Raeve, et al.
British Journal of Haematology
|
November 14, 2013
Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma
Michelle Fanale, Sarit Assouline, John Kuruvilla, et al.
American Journal of Hematology
|
May 26, 2016
A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL
Ian W Flinn, Panayiotis Panayiotidis, Boris Afanasyev, et al.
Clinical Hematology International
|
January 19, 2023
Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma
Torben Plesner, Simon J Harrison, Hang Quach, et al.
Blood
|
July 30, 2025
Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL
Jan A Burger, Paul M Barr, Tadeusz Robak, et al.
British Journal of Haematology
|
November 27, 2013
Peripheral blood involvement in patients with follicular lymphoma: a rare disease manifestation associated with poor prognosis
Clémentine Sarkozy, Lucile Baseggio, Pierre Feugier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 26, 2015
A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma
Markus Hansson, Peter Gimsing, Ashraf Badros, et al.
Blood
|
August 14, 2012
Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms
Hervé Ghesquières, Guillaume Cartron, John Francis Seymour, et al.
Targeted Oncology
|
October 23, 2021
Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study
Eliza A Hawkes, Tycel Phillips, Lihua Elizabeth Budde, et al.
Page
of 13